Net Cash Provided by (Used in) Financing Activities in USD of PLUS THERAPEUTICS, INC. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
PLUS THERAPEUTICS, INC. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2010 to Q1 2025.
  • PLUS THERAPEUTICS, INC. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $12,405,000.
  • PLUS THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $6,187,000, a 80% increase from 2023.
  • PLUS THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $3,445,000, a 74% decline from 2022.
  • PLUS THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $13,451,000, a 34% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

PLUS THERAPEUTICS, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $12,405,000 +$13,181,000 01 Jan 2025 31 Mar 2025 10-Q 30 May 2025 2025 Q1
Q1 2024 $776,000 -$1,269,000 -257% 01 Jan 2024 31 Mar 2024 10-Q 30 May 2025 2025 Q1
Q1 2023 $493,000 -$6,799,000 -93% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q1 2022 $7,292,000 -$1,899,000 -21% 01 Jan 2022 31 Mar 2022 10-Q 20 Apr 2023 2023 Q1
Q1 2021 $9,191,000 +$9,209,000 01 Jan 2021 31 Mar 2021 10-Q 21 Apr 2022 2022 Q1
Q1 2020 $18,000 -$1,909,000 -101% 01 Jan 2020 31 Mar 2020 10-Q 22 Apr 2021 2021 Q1
Q1 2019 $1,891,000 +$2,041,000 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q1 2018 $150,000 01 Jan 2018 31 Mar 2018 8-K 10 Sep 2019
Q1 2014 $6,895,000 +$6,563,000 +1977% 01 Jan 2014 31 Mar 2014 10-Q 12 May 2014 2014 Q1
Q1 2013 $332,000 -$4,884,000 -94% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q1 2012 $5,216,000 +$4,542,000 +674% 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013 2013 Q1
Q1 2011 $674,000 01 Jan 2011 31 Mar 2011 10-Q 10 May 2012 2012 Q1

PLUS THERAPEUTICS, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,187,000 +$2,742,000 +80% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $3,445,000 -$10,006,000 -74% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $13,451,000 -$6,965,000 -34% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $20,416,000 +$20,735,000 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2023 2022 FY
2020 $319,000 -$12,950,000 -103% 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
2019 $12,631,000 +$5,463,000 +76% 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2021 2020 FY
2018 $7,168,000 -$9,647,000 -57% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
2017 $16,815,000 01 Jan 2017 31 Dec 2017 8-K 10 Sep 2019
2013 $20,772,000 -$1,420,000 -6.4% 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2014 2013 FY
2012 $22,192,000 +$2,055,000 +10% 01 Jan 2012 31 Dec 2012 10-K 14 Mar 2014 2013 FY
2011 $20,137,000 -$44,541,000 -69% 01 Jan 2011 31 Dec 2011 10-K 14 Mar 2014 2013 FY
2010 $64,678,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.